跳至主要内容
临床试验/NCT02711670
NCT02711670已完成不适用

Night-time Use of Thiazide Diuretics for Improved Reduction in Stone Risk in Stone Formers With Elevated Urine Calcium

VA New York Harbor Healthcare System1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2014年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
10
试验地点
1
主要终点
Change in excretion and supersaturation of urine calcium oxalate / phosphate

研究概览

简要总结

Thiazide diuretics will be more effective in lowering urine calcium excretion if taken at night as compared to the daytime. It will therefore be more effective in reducing kidney stone recurrence in nephrolithiasis patients with elevated urine calcium who are known to have increased risk of kidney stones at night time.

详细描述

The study will be divided into three phases for every single patient, investigators will study 15-20 stone formers who have previously documented elevated urine calcium excretion, with a plan to measure their urine chemistries at baseline (if they currently use thiazide diuretics, they will come off of their respective thiazide for a 7-day washout period). Investigators will ask them to collect urine samples in two 12-hour intervals: on awakening, the 1st sample starts to before supper; 2nd sample begins after dinner and extends overnight with fasting after dinner, These measurements will be used as controls. Then patients will be started back on diuretics (25mg of chlorthalidone for the primary study; pending the results this may be repeated with 25mg of hydrochlorothiazide as a second substudy) which they will take in the daytime; after a 6-day acclimation period, two 12-hour urine samples will be collected as in the washout period. For the third study period, the patients will then begin taking the thiazide after dinner. After a 6-day acclimation period, the third set of urine collections will be done.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with recurrent calcium kidney stones (at least 2 episodes) and either a higher urine calcium excretion (urine Ca >200 mg/d or > 4 mg/kg body weight) or,
  • In patients who currently take a thiazide diuretic, a history of elevated urine calcium prior to medication use;
  • Also capable of signing consent and doing 24-hour urine collections repeatedly.

排除标准

  • Patients with primary hyperparathyroidism, renal tubular acidosis, chronic kidney disease (serum creatinine > 1.5 mg/dl), inflammatory bowel disease, gout,
  • Patients taking thiazides with a history of hypertension,
  • Patients with baseline systolic blood pressure less than 110mmHg

研究组 & 干预措施

thiazide

Experimental

Stone formers History of calcium containing kidney stones, hypercalciuria on previous urine tests, no kidney disease, not pregnant/lactating

干预措施: chlorthalidone (Drug)

thiazide

Experimental

Stone formers History of calcium containing kidney stones, hypercalciuria on previous urine tests, no kidney disease, not pregnant/lactating

干预措施: Hydrochlorothiazide (Drug)

结局指标

主要结局

Change in excretion and supersaturation of urine calcium oxalate / phosphate

时间窗: 1 week

次要结局

未报告次要终点

研究者

发起方
VA New York Harbor Healthcare System
申办方类型
Fed
责任方
Principal Investigator
主要研究者

David S. Goldfarb, M.D.

PI

VA New York Harbor Healthcare System

研究点 (1)

Loading locations...

相似试验